J. Goldman & Co LP Makes New $8.06 Million Investment in Ardelyx, Inc. $ARDX

J. Goldman & Co LP acquired a new stake in Ardelyx, Inc. (NASDAQ:ARDX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,579,828 shares of the biopharmaceutical company’s stock, valued at approximately $8,057,000. J. Goldman & Co LP owned approximately 0.63% of Ardelyx at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Knott David M Jr acquired a new stake in shares of Ardelyx in the first quarter worth $1,240,000. AIGH Capital Management LLC acquired a new stake in Ardelyx in the 2nd quarter valued at $16,320,000. Rubric Capital Management LP purchased a new stake in shares of Ardelyx in the first quarter worth about $11,147,000. Clay Northam Wealth Management LLC purchased a new stake in shares of Ardelyx in the second quarter worth about $1,704,000. Finally, Vanguard Group Inc. grew its stake in shares of Ardelyx by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company’s stock valued at $110,650,000 after buying an additional 610,162 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Analyst Ratings Changes

ARDX has been the topic of several recent research reports. BTIG Research reduced their price target on Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Citigroup dropped their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. LADENBURG THALM/SH SH initiated coverage on shares of Ardelyx in a research note on Tuesday, June 16th. They issued a “buy” rating and a $16.00 target price for the company. TD Cowen lowered their price target on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Zacks Research downgraded shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.90.

Insider Activity

In related news, CEO Michael Raab sold 58,574 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $226,095.64. Following the transaction, the chief executive officer directly owned 1,619,792 shares in the company, valued at $6,252,397.12. This trade represents a 3.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mike Kelliher sold 7,758 shares of Ardelyx stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $29,945.88. Following the completion of the transaction, the insider directly owned 349,660 shares of the company’s stock, valued at approximately $1,349,687.60. This represents a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 126,059 shares of company stock valued at $486,588 over the last three months. Company insiders own 5.30% of the company’s stock.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Ardelyx Stock Up 1.1%

ARDX stock opened at $3.78 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69. The firm has a 50 day simple moving average of $4.97 and a 200-day simple moving average of $5.75. The company has a market capitalization of $941.94 million, a P/E ratio of -17.18 and a beta of 0.70. Ardelyx, Inc. has a twelve month low of $3.72 and a twelve month high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%.Ardelyx’s revenue was up 34.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.08) earnings per share. On average, equities research analysts predict that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.